Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Alkermes PLC (ALKS) Insider Trading Activity

    Healthcare • Drug Manufacturers - Specialty & Generic • 2,100 employees

    Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

    Total Value

    -$4,064,755.75

    Total Shares

    -67,422

    Average Trade Value

    -$203,237.79

    Most Active Insider

    Hopkinson Craig C.

    Total Activity: $12,155,392

    Largest Single Transaction

    $3,234,382

    by Hopkinson Craig C. on Jan 30, 2025

    30-Day Activity

    5 Transactions

    Volume: 3,286 shares
    Value: $1,065,245

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    EVP Rd, Chief Medical Officer
    Officer
    Jan 30, 2025 23,542 $578,898 126,863 (+18.6%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Jan 30, 2025 26,589 $514,231 103,321 (+25.7%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Jan 30, 2025 100,918 $3,234,382 44,290 (-227.9%) Sale
    EVP Rd, Chief Medical Officer
    Officer
    Jan 30, 2025 29,156 $583,995 76,732 (+38.0%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Jan 30, 2025 18,345 $492,013 145,208 (+12.6%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Dec 9, 2024 61,151 $1,961,406 47,576 (-128.5%) Sale
    Director
    Dec 9, 2024 2,691 $85,708 23,013 (-11.7%) Sale
    EVP Rd, Chief Medical Officer
    Officer
    Dec 9, 2024 12,452 $249,414 72,182 (+17.3%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Dec 9, 2024 12,044 $296,162 96,316 (+12.5%) Exercise/Conversion
    Director
    Dec 9, 2024 2,691 $60,601 25,704 (+10.5%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Dec 9, 2024 12,411 $332,863 108,727 (+11.4%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Dec 9, 2024 12,090 $233,821 84,272 (+14.3%) Exercise/Conversion
    Director
    Dec 8, 2024 958 $30,139 23,013 (-4.2%) Payment of Exercise Price
    Director
    Dec 8, 2024 4,163 $10,000 23,971 (+17.4%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Dec 5, 2024 9,221 $290,462 59,730 (-15.4%) Sale
    EVP Rd, Chief Medical Officer
    Officer
    Dec 4, 2024 14,349 $441,550 68,951 (-20.8%) Sale
    Svp, Chief Commercial Officer
    Officer
    Nov 27, 2024 5,208 $151,813 60,703 (-8.6%) Sale
    EVP Rd, Chief Medical Officer
    Officer
    Nov 11, 2024 43,058 $862,452 142,296 (+30.3%) Exercise/Conversion
    EVP Rd, Chief Medical Officer
    Officer
    Nov 11, 2024 58,996 $1,774,576 83,300 (-70.8%) Sale
    EVP Rd, Chief Medical Officer
    Officer
    Nov 6, 2024 10,471 $309,169 99,238 (-10.6%) Sale